Immunovant CTO sells 40,000 shares in open market
Immunovant, Inc. Chief Technology Officer Jay S. Stout reported selling a total of 40,000 shares of Common Stock in open-market transactions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Immunovant, Inc. Chief Technology Officer Jay S. Stout reported selling a total of 40,000 shares of Common Stock in open-market transactions. The sales on June 26, 2026 were executed at weighted average prices of $38.18 and $38.94 per share, with individual trades occurring between $37.74 and $39.13 per share.
Insider Trade Summary
Net Seller: 40,000 shares
Net Sell
2 txns
Insider
Stout Jay S
Role
Chief Technology Officer
Sold
40,000 shs ($1.53M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 33,277 | $38.18 | $1.27M |
| Sale | Common Stock | 6,723 | $38.94 | $262K |
Holdings After Transaction:
Common Stock — 211,685 shares (Direct)
Footnotes (2)
- F1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.74 - $38.56 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.76 - $39.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Key Figures
Total shares sold: 40,000 shares
First transaction size: 6,723 shares
Second transaction size: 33,277 shares
+5 more
8 metrics
Total shares sold
40,000 shares
Combined open-market sales on June 26, 2026
First transaction size
6,723 shares
Common Stock sale with weighted average pricing
Second transaction size
33,277 shares
Common Stock sale with weighted average pricing
Weighted average price 1
$38.94 per share
First sale of Common Stock
Weighted average price 2
$38.18 per share
Second sale of Common Stock
Price range block 1
$37.74–$38.56 per share
Individual trades within first weighted average
Price range block 2
$38.76–$39.13 per share
Individual trades within second weighted average
Sell transactions count
2 transactions
Form 4 transaction summary
Key Terms
open-market sale, weighted average price, Common Stock, Form 4
4 terms
open-market sale financial
"Each transaction is described as an open-market sale of Common Stock."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported is a weighted average price for multiple transactions."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Common Stock financial
"The transactions involve sales of Common Stock of Immunovant, Inc."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"Full pricing details are available upon request as noted in this Form 4."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Immunovant (IMVT) CTO Jay S. Stout report in this Form 4?
Jay S. Stout reported selling Immunovant Common Stock in two open-market transactions. The filing shows a total of 40,000 shares sold on June 26, 2026, at weighted average prices around the high-$30 range per share.
Were Jay S. Stout’s Immunovant (IMVT) sales open-market transactions?
Yes, both transactions are described as open-market sales of Common Stock. The Form 4 uses transaction code “S” and specifies each as a sale in the open market or a private transaction at the reported weighted average prices.
Does this Immunovant (IMVT) Form 4 show any option exercises or derivatives?
No, the reported transactions involve only non-derivative Common Stock sales. The derivative summary section is empty, and there are no exercise prices, expiration dates, or underlying security details listed in the filing.
What is Jay S. Stout’s position at Immunovant, Inc. according to the Form 4?
Jay S. Stout is identified as an officer of Immunovant, Inc., serving as Chief Technology Officer. The filing indicates he is not listed as a director or a ten percent owner, but reports these transactions in his officer capacity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
